Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5678485 | 0.85 | LMNA (0.53) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26045534 | 0.83 | TSHR (0.48) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1730081 | 0.82 | LMNA (0.53) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL19935331 | 0.82 | LMNA (0.50) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28686366 | 0.81 | SMN1; SMN2 (0.56) | LMNATSHRF2ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL27431202 | 0.81 | LMNA (0.52) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26179405 | 0.80 | TSHR (0.46) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29114267 | 0.80 | CYP1A2 (0.46) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL229327 | 0.79 | TSHR (0.58) | LMNATSHRCYP1A2CYP2D6CYP2C19 | |
| SCHEMBL11526319 | 0.79 | LMNA (0.50) | LMNATSHRCYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-10 | — | — | US | disclosed |
| US-7566808-B2 | Management of ophthalmologic disorders, including macular degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-24 | — | — | US | disclosed |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LMNA 803/4885TSHR 878/4885CYP1A2 4526/4885 |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LMNA 817/4885TSHR 886/4885CYP1A2 4614/4885 |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | ALDH1A2, PDE6C, PDE6B | LMNA 112/4885TSHR 1122/4885CYP1A2 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.